Thirteen IPOs raised a combined $7.3 billion in April, joined by two direct listings. While surging volatility in March weighed on new issuance early on, activity ended in line with April’s 10-year historical average by deal count (15) but well above by...read more
Alamar Biosciences, which provides a protein biomarker detection platform for disease detection research, raised $191 million by offering 11.3 million shares at $17, the high end of the $15 to $17 range. The company sold 20% more shares than the 9.4 million...read more
Alamar Biosciences, which provides a protein biomarker detection platform for disease detection research, announced terms for its IPO on Monday. The Fremont, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to ...read more
Renaissance Capital’s April IPO Market Update
Thirteen IPOs raised a combined $7.3 billion in April, joined by two direct listings. While surging volatility in March weighed on new issuance early on, activity ended in line with April’s 10-year historical average by deal count (15) but well above by...read more
US IPO Weekly Recap: IPO calendar heats up as AI chipmaker Cerebras rejoins the public pipeline
Cerebras...read more
Protein biomarker detection platform Alamar Biosciences prices upsized IPO at $17, the high end of the range
Alamar Biosciences, which provides a protein biomarker detection platform for disease detection research, raised $191 million by offering 11.3 million shares at $17, the high end of the $15 to $17 range. The company sold 20% more shares than the 9.4 million...read more
Protein biomarker detection platform Alamar Biosciences sets terms for $150 million IPO
Alamar Biosciences, which provides a protein biomarker detection platform for disease detection research, announced terms for its IPO on Monday. The Fremont, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to ...read more